AMRI names Michael Mulhern CEO | January 15, 2018 Issue - Vol. 96 Issue 3 | Chemical & Engineering News
Volume 96 Issue 3 | p. 13 | Concentrates
Issue Date: January 15, 2018

AMRI names Michael Mulhern CEO

Department: Business
Keywords: Outsourcing, AMRI, private equity

Four months after being taken private by private equity firms, Albany Molecular Research Inc. (AMRI) announced that Michael Mulhern will replace William S. Marth as CEO. Mulhern was previously CEO of Sterigenics International, a specialist in sterilization, gamma technologies, and medical isotopes owned by GTCR, the investment firm that acquired AMRI in partnership with the Carlyle Group. Marth, who replaced the company’s founder, Tom D’Ambra, in 2013, will remain with the company in an advisory role, according to AMRI.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment